JP2023517078A5 - - Google Patents

Info

Publication number
JP2023517078A5
JP2023517078A5 JP2022554294A JP2022554294A JP2023517078A5 JP 2023517078 A5 JP2023517078 A5 JP 2023517078A5 JP 2022554294 A JP2022554294 A JP 2022554294A JP 2022554294 A JP2022554294 A JP 2022554294A JP 2023517078 A5 JP2023517078 A5 JP 2023517078A5
Authority
JP
Japan
Prior art keywords
composition according
administered
subject
approximately
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022554294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517078A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/021527 external-priority patent/WO2021183529A1/en
Publication of JP2023517078A publication Critical patent/JP2023517078A/ja
Publication of JP2023517078A5 publication Critical patent/JP2023517078A5/ja
Pending legal-status Critical Current

Links

JP2022554294A 2020-03-11 2021-03-09 ツカチニブを用いてher2突然変異を有するがんを処置する方法 Pending JP2023517078A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062988312P 2020-03-11 2020-03-11
US62/988,312 2020-03-11
PCT/US2021/021527 WO2021183529A1 (en) 2020-03-11 2021-03-09 Methods of treating her2 mutant cancers with tucatinib

Publications (2)

Publication Number Publication Date
JP2023517078A JP2023517078A (ja) 2023-04-21
JP2023517078A5 true JP2023517078A5 (cg-RX-API-DMAC7.html) 2024-03-19

Family

ID=75278374

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554294A Pending JP2023517078A (ja) 2020-03-11 2021-03-09 ツカチニブを用いてher2突然変異を有するがんを処置する方法

Country Status (9)

Country Link
US (1) US20230136203A1 (cg-RX-API-DMAC7.html)
EP (1) EP4118237A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023517078A (cg-RX-API-DMAC7.html)
KR (1) KR20220152287A (cg-RX-API-DMAC7.html)
CN (1) CN115698338A (cg-RX-API-DMAC7.html)
CA (1) CA3174986A1 (cg-RX-API-DMAC7.html)
IL (1) IL296227A (cg-RX-API-DMAC7.html)
MX (1) MX2022011160A (cg-RX-API-DMAC7.html)
WO (1) WO2021183529A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3615067A1 (en) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
KR20220086627A (ko) * 2019-10-21 2022-06-23 시아겐 인크. 카페시타빈 및 트라스투주맙과 조합으로 투카티닙을 사용하여 her2 양성 유방암을 치료하는 방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4683203A (en) 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
WO1993017668A1 (en) 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
WO2019241599A1 (en) * 2018-06-14 2019-12-19 Memorial Sloan Kettering Cancer Center Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies

Similar Documents

Publication Publication Date Title
AU2005314461B2 (en) Methods and compositions for treating ocular disorders
WO2017147594A1 (en) COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS
KR20210132045A (ko) 안지오포이에틴-유사 7(angtl7) 억제제를 사용하는 안구 질환의 트리트먼트
KR20230041709A (ko) G-단백질 결합 수용체 75 (gpr75) 억제제를 사용한 비만 치료
JP2026084693A (ja) TNFα拮抗薬を使用したドライアイ疾患の治療方法
US20180263979A1 (en) Combination of raf inhibitors and aurora kinase inhibitors
US20230136203A1 (en) Methods of treating her2 mutant cancers with tucatinib
WO2007106424A2 (en) Treating cancers with activated ras through inhibition of pkc delta
US12048699B2 (en) Cancer treatment methods based on TP53 mutation status and hypermutation
JP2009511057A (ja) 黄斑変性に関与する遺伝子
US20200316067A1 (en) Combination of raf inhibitors and taxanes
CN115244179A (zh) 用于治疗和预防前激肽释放酶相关疾患的组合物和方法
US20250075216A1 (en) Treatment Of Muscle Disorder With Folliculin Interacting Protein 1 (FNIP1) Inhibitors And/Or Folliculin (FLCN) Inhibitors
RU2812912C2 (ru) Лечение офтальмологических патологических состояний ингибиторами ангиопоэтин-подобного белка 7 (angptl7)
HK1113690B (en) Methods and compositions for diagnosing age-related macular degeneration
KR20170076480A (ko) Pint 유전자의 발현 저해제 또는 pint의 활성 저해제를 포함하는 조성물 및 그의 용도